A Study of Two Intravenous Anesthesia Methods in Breast Fibroadenoma Surgery

Comparison of Ketamine-Propofol and Ketamine-Dexmedetomidine for Total Intravenous Anaesthesia in Patients undergoing Fibroadenoma Breast Surgeries: A Randomised Double Blind Study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/107874

Enrollment

Registered

2026-04-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Dexmedetomidine-Ketamine: IV Dexmedetomidine 0.5mcg/kg in 10ml syringe diluted with NS over 10 minutes and Ketamine 0,5mg/kg IV bolus in 10ml syringe with NS to produce sedation Control

Eligibility

Inclusion criteria

Inclusion criteria: AGE MORE THAN EQUAL TO 16 YEARS OF ASA PHYSICAL STATUS I OR II IN FEMALE PATIENTS UNDERGOING ELECTIVE SURGERY FOR FIBROADENOMA BREAST.

Exclusion criteria

Exclusion criteria: Patient unwilling to participate,Pregnancy or Lactation,Cardiovascular Instability,Baseline Heart Rate less Than 50bpm,Patient requiring intraoperative airway support.

Design outcomes

Primary

Measure	Time frame
To Compare Sedation Quality between Dexmedetomidine-Ketamine and Propofol-Ketamine combintion In Patients Undergoing Fibroadenona Breast SurgeryTimepoint: T0-baseline. T1-5 mins after drug administration. T2-10 mins after drug administration.	—

Secondary

Measure	Time frame
To assess Hemodynamic instability. to assess incidence of respiratory depression in both groups. Timepoint: T0-baseline. T1-5 mins after drug administration. T2-10 mins after drug administration.	—

Countries

India

Contacts

Public ContactPriyanka Shrivastava

Rajendra Institute of Medical Sciences,RIMS Ranchi

shrivastava2911@gmail.com9958912712

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026